Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients.

BACKGROUND Previous studies in dialysis patients showed an association between haemoglobin levels and all-cause mortality, however, without addressing sex differences. METHODS We followed up 235 incident dialysis patients of the region of Vorarlberg in a prospective cohort study applying a time-dependent Cox regression analysis using all the measured laboratory values for up to more than 7 years. In total, 12 242 haemoglobin measurements with a median of 47 (range 3-270) per patient were available to evaluate the impact of haemoglobin levels and their variability on all-cause mortality in a sex-stratified analysis. Non-linear P-splines were used to allow a flexible modelling of the association with mortality. RESULTS We observed an inverse relationship between the increasing haemoglobin values and the decreasing risk of mortality. The linear component of the non-linear spline was highly significant for both men (P = 0.00005) and women (P = 0.0000000052). The non-linear component was also significant but less pronounced than the linear component. The inverse relationship was clear to see haemoglobin levels of up to 12-13 g/L in women, which reached a plateau for the higher values of haemoglobin. For men, an inverse trend was observed but clearly attenuated when compared to women. After adjustment for additional parameters of inflammation and malnutrition as well as diabetes, the linear component was more significant in women (P = 0.0018) than in men (P = 0.023). CONCLUSIONS This study applied for the first time a time-dependent Cox regression analysis over a long-term observation period of several years using all available measurements. Besides the methodological advantages, our data indicate a sex-specific linear as well as non-linear effect of haemoglobin levels on all-cause mortality, which was markedly more pronounced in women.

[1]  A. Covic,et al.  The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  F. Schmidt Meta-Analysis , 2008 .

[3]  R. Foley,et al.  Hemoglobin level variability: associations with mortality. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[4]  M. Joffe,et al.  Hemoglobin variability and mortality in ESRD. , 2007, Journal of the American Society of Nephrology : JASN.

[5]  Kdoqi KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007 .

[6]  H. Krum,et al.  Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis , 2007, The Lancet.

[7]  J. Berns,et al.  KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[9]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[10]  R. Foley,et al.  Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[11]  F. Kronenberg,et al.  Carotid plaques and their predictive value for cardiovascular disease and all-cause mortality in hemodialysis patients considering renal transplantation: a decade follow-up. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  A. Levin,et al.  Effect of early correction of anemia on the progression of CKD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  S. Greenland,et al.  Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.

[14]  K. Kalantar-Zadeh,et al.  Association of anemia with outcomes in men with moderate and severe chronic kidney disease. , 2006, Kidney international.

[15]  L. Arab,et al.  Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  P. Parfrey Target hemoglobin level for EPO therapy in CKD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  A. Levin,et al.  Sex, haemoglobin and kidney disease: new perspectives , 2005, European journal of clinical investigation.

[18]  J. Craig,et al.  Hypothesis versus association: the optimal hemoglobin target debate. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  J. Singer,et al.  Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  S. Fishbane,et al.  Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. , 2005, Kidney international.

[21]  R. Foley,et al.  Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. , 2005, Journal of the American Society of Nephrology : JASN.

[22]  M. Haugen,et al.  Dietary intake of differently fed salmon; the influence on markers of human atherosclerosis , 2005, European journal of clinical investigation.

[23]  Francesco Locatelli,et al.  Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  A. Collins,et al.  Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. , 2004, Kidney international.

[25]  David Voss,et al.  Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. , 2004, Journal of the American Society of Nephrology : JASN.

[26]  S. Fishbane,et al.  Hemoglobin variability in epoetin-treated hemodialysis patients. , 2003, Kidney international.

[27]  Eduardo Lacson,et al.  The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. , 2003, Kidney international.

[28]  A. Christensson,et al.  A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  J. Lazarus,et al.  Effect of variability in anemia management on hemoglobin outcomes in ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  L. Dworkin,et al.  Residual renal function and mortality risk in hemodialysis patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  A. Collins,et al.  Impact of hematocrit on morbidity and mortality. , 2000, Seminars in nephrology.

[32]  A. Levin,et al.  Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. , 2000, Kidney international.

[33]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[34]  J. Singer,et al.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  A. Collins,et al.  Hematocrit levels and hospitalization risks in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[36]  A. Collins,et al.  Hematocrit level and associated mortality in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[37]  Brian D. Marx,et al.  Generalized Linear Regression on Sampled Signals and Curves: A P-Spline Approach , 1999, Technometrics.

[38]  David C. Murray,et al.  The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  W. Schobersberger,et al.  Red cell oxygen transport in man in relation to gender and age , 1989, Mechanisms of Ageing and Development.